Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
About this episode
Daisy Wolf interviews Dr. Andrew Huberman about the impact of the pandemic on health, emerging peptides, focus drugs, and future neurotechnologies.
Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years.
More episodes of Raising Health
- Healthcare Will Benefit Most from AI | Julie Yoo on StartUp Health
- Rebuilding Behavioral Health’s Operating System with AI
- AI in Healthcare: The Leapfrog Opportunity
- Ambience CEO Nikhil Buduma on AI in Clinical Workflows
- Building the Marketplace for AI’s Most Valuable Asset
- Making Healthcare Affordable for 80 Million Americans
Explore listener stats, chart rankings, contacts and more on the Raising Health podcast page.